Sygnia Osi Fund: A Smart Investment Strategy

The Sygnia OSI (Oxford Sciences Innovation) fund is an innovative and exciting fund that creates change through Impact Investing. The fund prioritises investments in companies that are using technology-driven innovation to revolutionise healthcare and reduce the impact of climate change. With a high-risk profile, the fund invests in shares of Oxford Sciences Innovation Plc, a company that partners with the University of Oxford to convert patents and research ideas into commercial enterprises. To invest in the Sygnia OSI fund, individuals can do so through the RA, Pension Preservation, Endowment, and Living Annuity, with a minimum investment of R5,000.

The fund's focus on impact investing

The Sygnia OSI (Oxford Sciences Innovation) fund is an innovative fund that creates change through impact investing. Sygnia deploys 100% of its capital to generate socially impactful and sustainable long-term returns. The fund aims to achieve exceptional performance while changing lives by making the unaffordable and unachievable possible.

Impact investing is an investment strategy that involves investing in companies and organisations that generate a measurable, beneficial social or environmental impact, alongside financial returns for investors. Essentially, it allows investors to be part of the change they want to see while making a profit.

The Sygnia OSI fund invests in the shares of Oxford Sciences Innovation Plc, a company that partners with the University of Oxford to convert its patents and research ideas into commercial enterprises. OSI prioritises investments in companies that use technology-driven innovation to revolutionise healthcare and reduce the impact of climate change. For example, OSI has invested in companies such as Evox Therapeutics, which modifies exosomes to facilitate targeted drug delivery to organs such as the brain and central nervous system, and Osler Decentralised Diagnostics, which has created a portable diagnostic device that enables anyone to test for a majority of biomarkers from a single drop of blood.

By investing in these types of companies, the Sygnia OSI fund focuses on impact investing by supporting businesses that are making a positive impact on humanity while also generating financial returns.

The companies Sygnia OSI invests in

The Sygnia OSI fund invests in shares of Oxford Sciences Innovation (OSI) Plc and select spin-out companies from the University of Oxford. The fund prioritises companies that use technology-driven innovation to revolutionise healthcare and reduce the impact of climate change.

Some of the companies that the Sygnia OSI fund invests in include:

• Evox Therapeutics: Evox Therapeutics modifies exosomes to facilitate targeted drug delivery to organs such as the brain and the central nervous system.
• Osler Decentralised Diagnostics: Osler has created a portable diagnostic device that enables anyone, anywhere to test for a majority of biomarkers quickly, cheaply and accurately from just a single drop of blood.
• Ultromics AI of Echocardiography: Ultromics uses ultrasound technology to reduce the error rate in the diagnosis of coronary heart disease by more than 50%.
• Vaccitech: Vaccitech is a clinical-stage T-cell immunotherapy company that creates novel vaccines that elicit strong responses from T-cells to treat and prevent infectious diseases.

The fund's high-risk profile

The Sygnia OSI fund has a high-risk profile due to several factors. Firstly, it invests in Oxford Sciences Innovation (OSI) Plc, a company that focuses on commercialising the patents and research ideas of the University of Oxford. This involves investing in unlisted companies, which typically carry higher risks than listed companies. OSI acts as a seed investor, deploying capital in specific investment opportunities with potential future value in fields like genomics, AI, fintech, and quantum computing. This early-stage investing can be risky as the potential for high growth must be balanced against the possibility of failure or underperformance.

Secondly, as an offshore fund, Sygnia OSI is exposed to general market risk, exchange rate risk, liquidity risk, and legal and regulatory risks. These factors can significantly impact the fund's performance and are often beyond the control of the fund managers. Exchange rate fluctuations, in particular, can affect the value of investments and impact the returns for investors.

Additionally, the fund's focus on technology-driven innovation and impact investing adds to its risk profile. While investing in innovative companies with a positive impact on healthcare and climate change is appealing, these companies may face unique challenges and uncertainties. The success of their products and services may depend on various factors, including regulatory approval, market acceptance, and competition from established companies.

Furthermore, the fund's performance is tied to the success of OSI's investment strategy. OSI's Investment Principals work closely with academics to turn patents into spin-out businesses, and there is a risk that these ventures may not succeed or generate the expected returns. While OSI's ideas are based on rigorous scientific research and backed by Oxford University, the commercialisation process carries its own set of risks and challenges.

Overall, the Sygnia OSI fund offers exciting opportunities for investors seeking impact investing and innovative companies. However, it is essential to carefully consider the fund's high-risk profile and understand that the potential for high returns comes with a higher level of risk.

The minimum investment amount

The fund is a Life Policy and is available through RA, Pension Preservation, Endowment, and Living Annuity. It is not a collective investment.

The Sygnia OSI fund invests in the shares of Oxford Sciences Innovation Plc. Oxford Sciences Innovation partners with the University of Oxford to convert patents and research ideas into commercial enterprises and successful spin-out companies. The fund prioritises investments in companies that use technology-driven innovation to revolutionise healthcare and reduce the impact of climate change.

The fund is an exciting opportunity to be part of impactful change while making a return on investment.

How to get in touch to invest

To get in touch with a view to investing in the Sygnia OSI fund, you can contact Maysure Financial Services, who provide information on the fund and can be reached by phone or email. Their contact number is +27 11 839 2302, and their email address is [email protected].

You can also contact Thuthuka SA for more information on the fund and how to invest. Their email address is [email protected].

The Sygnia OSI fund is an exciting opportunity for investors who want to see social change and make a financial return. The fund invests in companies that generate measurable, beneficial social or environmental impact. The portfolio includes companies such as Evox Therapeutics, Osler Decentralised Diagnostics, Ultromics AI of Echocardiography, and Vaccitech.

The fund is available through RA, Pension Preservation, Endowment, and Living Annuity. The minimum investment is R5,000, and this can be a one-off payment or made monthly.

Frequently asked questions